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Abstract: Capecitabine is currently the only novel, orally home-administered ﬂ  uorouracil 
prodrug. It offers patients more freedom from hospital visits and less inconvenience and compli-
cations associated with infusion devices. The drug has been extensively studied in large clinical 
trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many 
others. Furthermore, the drug compares favorably with ﬂ  uorouracil in patients with such can-
cers, with a safe toxicity proﬁ  le, consisting mainly of gastrointestinal and dermatologic adverse 
effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, 
the tolerability proﬁ  le is comparatively favorable. Prompt recognition of severe adverse effects 
is the key to successful management of capecitabine. Ongoing and future clinical trials will 
continue to examine, and likely expand, the role of capecitabine as a single agent and/or in 
combination with other anticancer agents for the treatment of gastrointestinal as well as other 
solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the 
current data on the role of capecitabine in the management of gastrointestinal cancers.
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Introduction
Fluoropyrimidines remain the standard treatment regimens for numerous types of 
solid tumors. Capecitabine (Xeloda®, Hoffmann-La Roche Inc., Nutley, New Jersey, 
USA), a thymidine phosphorylase (TP)-activated ﬂ  uoropyrimidine carbamate, is the 
only universally approved orally administered ﬂ  uoropyrimidine. It belongs to a newer 
generation of orally administered ﬂ  uoropyrimidines. The clinical need for convenient, 
tolerable and efﬁ  cient agents that do not require continuous infusion like the original 
ﬂ  uorinated analog of uracil, 5-ﬂ  uorouracil (5-FU), prompted the development of 
capecitabine.
Chemistry
5-FU is not clinically useful when administered orally because extensive metabolism 
by dihydropyrimidine dehydrogenase (DPD) in the mucosa of the gastrointestinal 
tract and the liver leads to highly variable bioavailability. Capecitabine (Figure 1) 
is an oral prodrug of 5-FU that is absorbed intact through the intestinal wall and 
then converted to 5-FU in three sequential enzymatic reactions.1 The ﬁ  nal requisite 
enzyme, thymidine phosphorylase, is present at consistently higher levels in tumor 
rather than normal tissues, thereby suggesting that 5-FU delivered in this way may 
beneﬁ  t from an element of tumor targeting and thus enhanced selectivity and better 
tolerability.2 Clinical evidence to support this comes from a study in patients with 
colorectal cancer. Capecitabine was administered 7 days before planned resec-
tion of the primary cancer and 5-FU levels assayed in tumor and adjacent tissues. OncoTargets and Therapy 2009:2 30
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The median ratio of 5-FU concentration in colorectal tumors 
to adjacent tissues was 2.9 (range 0.9–8.0).3
Clinical pharmacology
Capecitabine is relatively non-cytotoxic in vitro and is 
readily absorbed from the gastrointestinal tract. In the liver, a 
60 kDa carboxyesterase hydrolyzes much of the compound to 
5’-deoxy-5-ﬂ  uorocytidine (5’-DFCR). Cytidine deaminase, an 
enzyme found in most tissues, including tumors, subsequently 
converts 5’-DFCR to 5’-deoxy-5-ﬂ  uorouridine (5’-DFUR). 
The enzyme thymidine phosphorylase (dThdPase) then 
hydrolyzes 5’-DFUR to the active drug 5-FU. Many tissues 
throughout the body express thymidine phosphorylase4 and 
some human carcinomas including adenocarcinomas of the 
pancreas express this enzyme in higher concentrations than 
surrounding normal tissues.5
Both normal and tumor cells metabolize 5-FU to 
5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 
5-ﬂ  uorouridine triphosphate (FUTP). These metabolites 
cause cell injury by two different mechanisms. Firstly 
FdUMP and the folate cofactor, N5-10-methylenetetrahydro-
folate, bind to thymidylate synthase (TS) to form a covalently 
bound ternary complex. This binding inhibits the formation 
of thymidylate from 2’-deaxyuridylate. Thymidylate is the 
necessary precursor of thymidine triphosphate, which is 
essential for the synthesis of DNA, so that a deﬁ  ciency of 
this compound can inhibit cell division. Secondly nuclear 
transcriptional enzymes can mistakenly incorporate FUTP 
in place of uridine triphosphate (UTP) during the synthe-
sis of RNA. This metabolic error can interfere with RNA 
processing and therefore protein synthesis.
Pharmacokinetics and metabolism
The pharmacokinetics of capecitabine and its metabolites have 
been evaluated in a number of studies over a dosage range of 
500 to 3500 mg/m2/day.3 Over this range the pharmacokinetics 
of capecitabine and its metabolite, 5’-DFCR, were linear and 
did not alter with time. The increases in the areas under curves 
(AUCs) of 5’-DFUR and 5-FU, however, were greater than 
proportional to the increase in dose and the AUC of 5-FU was 
34% higher on day 14 than on day 1. The elimination half-life 
of both parent capecitabine and 5-FU was about 45 minutes. 
The inter-patient variability in the Cmax and AUC of 5-FU was 
greater than 85%. Capecitabine reached peak blood levels (Tmax) 
in about 1.5 hours with peak 5-FU levels occurring slightly later, 
at 2 hours. Food reduced both the rate and extent of absorption 
of capecitabine with mean Cmax and AUC decreased by 60% 
and 35%, respectively. The Cmax and AUC of 5-FU were also 
reduced by food by 43% and 21%, respectively. Food delayed 
Tmax of both parent and 5-FU by 1.5 hours. Plasma protein 
binding of capecitabine and its metabolites is less than 60% 
and is not concentration-dependent. Capecitabine was primarily 
bound to human albumin (approximately 35%).
Capecitabine is extensively metabolized enzymatically 
to 5-FU (Figure 2). The enzyme dihydropyrimidine dehy-
drogenase (DPD) hydrogenates 5-FU to the much less toxic 
5-ﬂ  uoro-5,6-dihydro-ﬂ  uorouracil (FUH2). Dihydropyrimidinase 
cleaves the pyrimidine ring to yield 5-ﬂ  uoro-ureido-propionic 
acid (FUPA). Finally beta-ureido-propionase cleaves FUPA 
to alfa-ﬂ  uoro-beta-alanine (FBAL) which is cleared in the 
urine. Capecitabine and its metabolites are predominantly 
excreted in urine; 95.5% of administered capecitabine dose 
is recovered in urine.6 Fecal excretion is minimal (2.6%). The 
major metabolite excreted in urine is FBAL which represents 
57% of the administered dose. About 3% of the administered 
dose is excreted in urine as unchanged drug.
Capecitabine has been evaluated in patients with mild to 
moderate hepatic dysfunction due to liver metastases deﬁ  ned 
by a composite score including serum levels of bilirubin, 
aspartate and alanine transaminases and alkaline phosphatase.7 
Following a single 1255 mg/m2 dose of capecitabine both 
AUC and Cmax of capecitabine increased by 60% compared to 
patients with normal hepatic function (n = 14). Although the 
AUC and Cmax of 5-FU was not affected capecitabine should 
be administered with caution in patients with even mild hepatic 
dysfunction and avoided in the presence of more severe liver 
impairment. There does not appear to be an effect on the phar-
macokinetics of capecitabine or 5-FU with declining creatinine 
clearance but levels of 5-DFUR and FBAL do rise signiﬁ  cantly 
once the creatinine clearance falls by more than 50%.8
Drug interactions
In vitro enzymatic studies with human liver microsomes indi-
cated that capecitabine and 5’-DFUR had no inhibitory effects 
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Capecitabine: 5’-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine.
Molecular weight = 359.35. 
Figure 1 Structure of capecitabine.OncoTargets and Therapy 2009:2 31
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on substrates of cytochrome P450, suggesting a low likelihood 
of interactions with drugs metabolized by cytochrome P450 
enzymes. However an important interaction exists between 
capecitabine and warfarin, resulting in exaggerated anticoagu-
lant activity and requiring close monitoring of the INR if these 
drugs are co-administered.9 The exact mechanism of the inter-
action is uncertain. An additional interaction occurred when 
Maalox® (20 mL), an aluminium hydroxide- and magnesium 
hydroxide-containing antacid, was administered immediately 
after capecitabine (1250 mg/m2). AUC and Cmax increased by 
16% and 35%, respectively for capecitabine and by 18% and 
22%, respectively, for 5’-DFCR. No effect was observed on 
the other three major metabolites (5’-DFUR, 5-FU, FBAL) 
of capecitabine.10
Summary of safety and tolerability
Capecitabine is relatively non-cytotoxic in vivo and thus the 
toxicity proﬁ  le reﬂ  ects that of its active metabolite 5-FU. The 
toxicity of 5-FU is known to be schedule-dependent. Bolus 
5-FU causes mainly diarrhea, oral mucositis, myelosuppres-
sion and ocular irritation while infusional schedules may 
cause hand-foot syndrome (HFS) and ulcers on the lips but 
rarely result in signiﬁ  cant myelosuppression. Interestingly 
the toxicity of capecitabine lies somewhere between that of 
bolus and infusional 5-FU.11 Diarrhea occurs in up to 50% of 
patients and may be severe, requiring hospital admission 
for intravenous (iv) ﬂ  uids and antibiotics if accompanied 
by neutropenia. About half the patients treated will also 
develop a degree of HFS which may be helped by the use of 
pyridoxine (vitamin B6). Many patients indicate that fatigue 
is often the most disruptive side effect of all and this may 
continue for some time after treatment has ended. Diarrhea 
occurs in around half the patients who receive capecitabine. 
This can be quite severe but is usually well controlled with 
medication. Mouth ulcers may occur and nausea and/or 
vomiting affect 30% of patients but is readily controlled 
with antiemetics. Occasional side effects include constipa-
tion, headaches, conjunctivitis, anorexia, abdominal pain, 
hair thinning, ankle swelling and chest pain due to coronary 
vasospasm.12
Clinical activity
Capecitabine is currently approved by the FDA for use as 
ﬁ  rst-line therapy in patients with metastatic colorectal cancer 
when single-agent ﬂ  uoropyrimidine therapy is preferred. The 
drug is also approved for use as a single agent in metastatic 
breast cancer patients who are resistant to both anthracycline- 
and paclitaxel-based regimens or in whom further anthracy-
cline treatment is contra-indicated and in combination with 
docetaxel after failure of prior anthracycline-based chemo-
therapy.13 Single-agent and combination regimens have also 
shown beneﬁ  ts in patients with prostate, pancreatic, renal cell, 
and ovarian cancers. Improved tolerability and comparable 
efﬁ  cacy compared with iv 5-FU/LV (5-FU with leucovorin) 
in addition to oral administration make capecitabine an attrac-
tive option for the treatment of several types of cancers as 
well as the focus of future trials.
Colorectal cancer
For more than 40 years, 5-FU has been the foundation treat-
ment for metastatic colorectal cancer and has been used 
with LV or in combination with irinotecan or oxaliplatin. As 
ﬁ  rst-line therapy in colon cancer patients capecitabine has 
been studied either as single-agent administration com-
pared directly to iv 5-FU/LV in two large randomized 
phase III trials14 or in combination with irinotecan15,16 and 
oxaliplatin17–20 in non-comparative studies. In the adjuvant 
setting a large randomized phase III trial (X-ACT study), 
enrolling 1987 Dukes C colon cancer patients, was conducted 
comparing single-agent capecitabine administration with iv 
5-FU/LV (Mayo Clinic regimen).21–23
In the ﬁ  rst-line monotherapy setting, the two random-
ized, prospective phase III trials enrolled a total number of 
1207 patients, who were randomized to receive either oral 
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Figure 2 Metabolism of capecitabine to 5-ﬂ  uorouracil.OncoTargets and Therapy 2009:2 32
Saif
capecitabine (1250 mg/m2 bid 2 weeks on/1 week off in 
3-week cycles) or the Mayo Clinic regimen (LV 20 mg/m2 
followed by 5-FU 425 mg/m2 iv bolus on days 1–5 in a 
4-week cycle)24,25 (Figure 3). Capecitabine demonstrated 
a statistically signiﬁ  cant superior objective response rate 
(ORR) compared with 5-FU/LV (26% vs 17%; p   0.0002), 
even in a patient subpopulation with poor prognostic param-
eters. Time to progression (TTP) was equivalent in both arms 
(4.6 vs 4.7 months; p = 0.85) and the same was revealed for 
overall survival (OS) (12.9 vs 12.8 months; p = 0.48).51 As far 
as the safety proﬁ  le was concerned, all-grade AEs, including 
diarrhea (47.7% vs 58%; p   0.001), stomatitis (24.3 vs 
61.6%; p   0.001), nausea (87.9 vs 47.6%; p   0.001), 
alopecia (5 vs 20.6%; p   0.001) and neutropenia requiring 
medical intervention (1.2% vs 10.5%; p   0.001) occurred 
signiﬁ  cantly more frequently in the 5-FU/LV arm. HFS 
was the only AE occurring in signiﬁ  cantly higher incidence 
with capecitabine (55.5% vs 62%; p   0.001). In addition, 
grade 3/4 stomatitis (2% vs 14.7%; p   0.001) and grade 
3/4 neutropenia (2.3% vs 22.8%; p   0.001) resulting in a 
signiﬁ  cantly higher incidence of neutropenic fever and sepsis 
(0.2% vs 3.4%, p   0.001), were more frequently observed 
with 5-FU/LV, whereas grade 3 HFS (17.1 vs 0.7%) occurred 
more frequently with capecitabine. Grade 3 hyperbilirubine-
mia appeared more frequently (18.3% vs 3.3%; p   0.001) 
in the capecitabine group but tended to be an isolated 
phenomenon involving only indirect bilirubin. Recently, a 
meta-analysis of the medical resource used in one of the trials 
demonstrated that single-agent capecitabine as monotherapy 
treatment for advanced, metastatic colorectal cancer, apart 
from being efﬁ  cient and more tolerable than 5-FU/LV, also 
led to substantial reduction in medical resource use.26
Capecitabine has been also evaluated as ﬁ  rst-line treatment 
in metastatic colorectal cancer patients in combination either 
with oxaliplatin17–20 or with irinotecan15,16 in non-comparative 
phase II studies. When administered in combination with 
oxaliplatin (120 mg/m2 on day 1 or 70 mg/m2 on days 1 
and 8), the dose of capecitabine varied between 750 mg/m2 
bid and 1250 mg/m2 on days 1–14 followed by 7 days rest in 
a 3-week cycle.19–22 Capecitabine has been also evaluated as 
ﬁ  rst-line treatment in metastatic colorectal cancer patients in 
combination either with oxaliplatin15–19 or with irinotecan19–22 
in phase II–III studies. When administered in combination 
with oxaliplatin (130 mg/m2 on day 1 or 70 mg/m2 on days 1 
and 8), the dose of capecitabine varied between 750 mg/m2 
bid and 1250 mg/m2 on days 1–14 followed by 7 days rest in 
3-week cycle.19–20 Cassidy et al reported a two-arm, random-
ized, noninferiority, phase III study (XELOX-1; NO16966A) 
comparing XELOX with FOLFOX-4 in the ﬁ  rst-line treatment 
of MCRC.27 After the pivotal phase III data for bevacizumab 
became available28 the protocol was amended to a random-
ized, 2 × 2 factorial design with two coprimary objectives. 
The intent-to-treat population comprised 634 patients from 
the original two-arm portion of the study, plus an additional 
1400 patients after the start of the amended 2 × 2 design, for 
a total of 2034 patients. The median PFS was 8.0 months in 
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Figure 3 Xeloda vs 5-FU/LV integrated analysis equivalent survival with Xeloda and 5-FU/LV in metastatic CRC.  Adapted with permission from Twelves C; Xeloda Colorectal Cancer 
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the pooled XELOX-containing arms versus 8.5 months in the 
FOLFOX-4–containing arms (hazard ratio [HR], 1.04; 97.5% 
CI, 0.93–1.16). The median overall survival was 19.8 months 
with XELOX versus 19.6 months with FOLFOX-4 (HR, 0.99; 
97.5% CI, 0.88–1.12). FOLFOX-4 was associated with more 
grade 3/4 neutropenia/granulocytopenia and febrile neutro-
penia than XELOX, and XELOX with more grade 3 diarrhea 
and grade 3 hand-foot syndrome than FOLFOX-4.28 The main 
reasons for discontinuation were diarrhea28 and sensory neu-
ropathy. In only one study did the initial dose of capecitabine 
have to be modiﬁ  ed from 1000 mg/m2 bid to 750 mg/m2 bid, 
because of the high incidence (85%) of diarrhea.
When administered concurrently with irinotecan, the dose 
of capecitabine ranged from 1000 mg/m2 to 1250 mg/m2 bid 
on days 1–14 followed by 1 week rest for 21 days, while 
irinotecan was delivered at dose 240 mg/m2  to 300 mg/m2  
on day 1 or 100 mg/m2 to 150 mg/m2 on days 1 and 8 in 
3-week cycles.15,16,29,30 In the study conducted by Bajetta 
et al16 (capecitabine 1250 mg/m2 bid days 1–14 and irino-
tecan 300 mg/m2 day 1 or 150 mg/m2 days 1, 8 in 3-week 
cycles) initial dose of both agents had to be modiﬁ  ed to a 
lower dose (capecitabine 1000 mg/m2 bid and irinotecan 
240 mg/m2 day 1 or 120 mg/m2 days 1, 8) because of the 
increased incidence ( 33%) of grade 3/4 diarrhea. Recently, 
a phase I/II pharmacokinetic study has demonstrated that the 
maximum tolerated dose of capecitabine is 1000 mg/m2 bid 
days 1–14 every 3 weeks, when concurrently administered 
with irinotecan in chemo-naïve colorectal cancer patients. 
The recommended dose of the latter is 250 mg/m2 on day 1.31 
The ORR in all studies ranged from 42% to 49%, which is 
similar to the results previously reported with FOLFIRI.30,32 
The most common grade 3/4 AEs were diarrhea (19%–27%), 
neutropenia (11%–12%) and nausea/vomiting (10%–12%). 
In all studies, the incidence of grade 3 HFS secondary to 
capecitabine was lower compared with the one experienced 
with capecitabine alone. Although no comparative trial was 
performed, grade 3/4 neutropenia occurred less frequently 
(11%–12% vs 46%) than with FOLFIRI, whereas the 
incidence of grade 3/4 diarrhea was higher. Both capecitabine 
combinations either with oxaliplatin or with irinotecan 
revealed comparable efﬁ  cacy with FOLFOX4 and FOLFIRI, 
respectively, with acceptable safety and tolerability. The 
results of ongoing randomized comparative phase III trials 
will ascertain the future of these combinations in the ﬁ  rst-line 
treatment of colorectal cancer.
In the adjuvant setting, capecitabine has been admin-
istered either as monotherapy or in combination with 
oxaliplatin. In a randomized, multicenter, comparative 
phase III trial (X-ACT) 1987 Dukes C resected colon cancer 
patients were randomized to receive as adjuvant treatment 
either single-agent capecitabine (1250 mg/m2 bid days 
1–14 every 21 days [n = 1004]) or the Mayo Clinic regi-
men (LV 20 mg/m2 iv followed by bolus iv administration 
of 5-FU, 425 mg/m2 on days 1–5 every 28 days, [n = 983]) 
over a period of 24 weeks.33 The X-ACT study demonstrated 
a signiﬁ  cantly superior relapse-free survival (p = 0.053) and 
trends toward superior disease-free survival (p = 0.053) 
and OS (p = 0.071) for the capecitabine arm (Figure 4). 
In addition, a positive safety proﬁ  le was observed with 
capecitabine, producing signiﬁ  cantly less of all grades of 
diarrhea (46 vs 64%; p   0.001), nausea/vomiting (36% vs 
51%; p   0.001), stomatitis (22% vs 60%; p   0.001), 
alopecia (6% vs 22%; p   0.001) and neutropenia (32 vs 
63%; p   0.001) (Figure 5). HFS was more frequently 
observed (60% vs 9%; p   0.001) with capecitabine. 
In addition, grade 3/4 neutropenia (2% vs 26%; p   0.001) 
leading to febrile neutropenia and consequently to sepsis 
(0.3% vs 3%; p   0.001), and stomatitis, (2% vs 14%; 
p   0.001) were signiﬁ  cantly more common in the 5-FU 
arm. Grade 3 hyperbilirubinemia ( 3 times the upper limit 
of normal) was more common with capecitabine (18% vs 
5.9%). The incidence of grade 3/4 abnormalities of the 
hepatic enzymes (serum glutamic-oxoacetic transaminase, 
serum glutamate-pyruvate transaminase), however, was 
low in both treatment arms (0.7% and 1.6%, respectively, 
with capecitabine, and 0.3% and 0.6%, respectively, with 
5-FU/LV).
The safety profile of capecitabine was similar, 
regardless of patients’ age ( 65 or  65 years of age). 
The incidence of ﬁ  rst and second dose reduction was 
higher in patients receiving 5-FU/LV (42% and 13%, 
respectively, for capecitabine, and 44% and 26%, respec-
tively, for the latter). In addition, median time to ﬁ  rst 
and second dose reduction was longer with capecitabine, 
compared with 5-FU/LV (78 and 113 days, respectively, 
for capecitabine, and 41 and 57 days, respectively, with 
5-FU/LV). Premature withdrawal was infrequent in 
both treatment arms (16 vs 12%). These results led the 
FDA to approve capecitabine as single-agent adjuvant 
therapy for Dukes C colon cancer patients, when single 
ﬂ  uoropyrimidine therapy is preferred.
In another randomized phase III trial in Dukes C colon 
cancer patients, three arms of adjuvant chemotherapy were 
compared: XELOX (capecitabine at dose 1000 mg/m2 bid 
days 1–14 plus oxaliplatin 130 mg/m2 on day 1, every 21 days 
for 8 cycles); Mayo Clinic regimen (LV 20 mg/m2 iv bolus OncoTargets and Therapy 2009:2 34
Saif
plus 5-FU 425 mg/m2 iv bolus on days 1–5, every 28 days 
for 6 cycles); and Roswell Park regimen (LV 500 mg/m2 iv 
plus iv 5-FU 500 mg/m2 on day 1, weeks 1–6, in four 8-week 
cycles). Early safety data were presented at the American 
Society of Clinical Oncology 2005 meeting.34 XELOX 
compared favorably with the other arms of the study. Grade 
3/4 neutropenia (5.3 vs 14 vs 3% respectively), febrile 
neutropenia (0.2% vs 4.7% vs 1.7% respectively), and also 
Disease-free survival Disease-free survival
∗Statistical test for superiority. 
3-year event-free rates
Xeloda: 66.0% 
5-FU/LV: 62.9% 
Hazard ratio = 0.87
(95% CI: 0.76-1.00)
Log-rank
p = 0.055*
Xeloda vs 5-FU/LV: DFS
1.0
0.8
 0.6
0
012345 6
E
s
t
i
m
a
t
e
d
 
P
r
o
b
a
b
i
l
i
t
y
0.4
Years
Xeloda (N = 1,004)
5-FU/LV (N = 983)
Figure 4 X-ACT: Adjuvant Xeloda vs 5-FU/LV. Adapted from Twelves C, et al. N Engl J Med. 2005;352:2696–2704.23
* *
Diarrhea
Neutropenic
fever/sepsis
Stomatitis Hand-foot
syndrome
Neutropenia† Nausea/
vomiting
Patients (%)
* *
80
70
60
50
40
30
20
10
0
Xeloda (n = 993)
Bolus 5-FU/LV (n = 974)
*p < 0.001
†Laboratory value
Figure 5 Adjuvant Xeloda: safety proﬁ  le versus bolus 5-FU/LV (grade 3/4).   Adapted from Scheithauer W, McKendrick J, Begdie S, et al. Oral capecitabine as an alternative to iv 
5-FU-based adjuvant therapy for colon cancer: safety results of a randomized phase III trial. Ann Oncol. 2003;14:1735–1743. By permission of Oxford University Press.OncoTargets and Therapy 2009:2 35
Capecitabine in GI cancers
stomatitis (0.6% vs 11.2% vs 0%, respectively) were less 
frequently observed with XELOX than with other treatment 
arms. Grade 3 HFS (3.6% vs 0.2% vs 0.2%, respectively), 
sensory neuropathy (8.1% vs 0 vs 0%), and vomiting (5% vs 
1.7% vs 4.6%) occurred more frequently with XELOX 
compared with the other two arms. The incidence of grade 
3/4 diarrhea was approximately the same with XELOX and 
the Mayo Clinic regimen (15% vs 13.5%, respectively), but 
higher with Roswell Park regimen (26.2%). Early safety 
results of XELOX administration are comparable with those 
of the FOLFOX regimen, the standard adjuvant therapy for 
colon cancer patients.35 Efﬁ  cacy results will be available 
in 2008.
The proven efﬁ  cacy and safety beneﬁ  ts of capecitabine 
over iv 5-FU/LV in the treatment of metastatic and early 
stage colon cancer have led to the development of a number 
of studies evaluating the use of capecitabine in chemora-
diation schedules for patients with locally advanced rectal 
cancer (LARC) as single agent as well as in combination 
with oxaliplatin or irinotecan. Although several dosing and 
schedule protocols of single-agent capecitabine combined 
with radiotherapy for locally advanced rectal cancer patients 
have been evaluated in several noncomparative phase II 
trials,36–40 the continuous administration of capecitabine at 
a dose of 825 mg/m2 bid concurrently with radiotherapy 
was the most applied. We retrospectively compared the 
safety and efﬁ  cacy of capecitabine-based regimens with 
well-established CIV-5-FU-based (continuous intravenous 
infusion 5-FU) regimens in LARC.41 We collected published 
data on 542 patients treated on either CIV-5-FU (197) or 
capecitabine (345) with concurrent radiation (external 
radiation treatment, XRT) for LARC. This included phase 
I or II studies published or available from Pubmed. Safety 
was assessed by determining proportion of patients who 
experienced grade III/IV adverse effects. Efﬁ  cacy was 
assessed by determining pathological complete response 
(pCR). Chi-square tests were used to compare the two regi-
mens. A p value less than 0.05 was considered statistically 
signiﬁ  cant. Statistical tests were further corrected for mul-
tiplicity using the method of Benjamini and Yekutieli. We 
found that pCR was signiﬁ  cantly higher in patients getting 
capecitabine vs CIV-5-FU (25 vs 13%; p = 0.008, P [adj] = 
0.034). Both regimens were generally well tolerated. There 
was no grade IV toxicity reported. Grade III HFS was more 
common in the capecitabine group, and grade III diarrhea 
was more common in the CIV group. Capecitabine appears 
to be tolerable, with no reported grade 4 AEs in most studies, 
and low incidence of grade 3 toxicities. Additionally, it 
is more convenient than protracted infusion of 5-FU and 
demonstrates comparable efﬁ  cacy achieving satisfactory 
tumor down-staging rates and pathological response rates. 
The same observation was made for concurrent administra-
tion of XELOX and XELIRI with radiotherapy.42–47 In light 
of the encouraging results, two large randomized phase III 
trials are in progress. The National Surgical Adjuvant Breast 
and Bowel Project R-04 trial is recruiting patients to 
receive either radiotherapy plus capecitabine ± oxaliplatin 
or plus infusional 5-FU ± oxaliplatin. Following surgery, 
patients will be administered FOLFOX ± bevacizumab. 
The Pan-European Trials in Adjuvant Colorectal Cancer 
6 trial compares neoadjuvant capecitabine plus radia-
tion followed by adjuvant capecitabine with or without 
oxaliplatin.
Gastric or gastroesophageal cancer
Capecitabine is being investigated in phase I–III trials for 
the treatment of gastric, gastroesophageal, and esophageal 
cancers, both in the ﬁ  rst-line metastatic setting as well 
as in the adjuvant setting. The most frequently investi-
gated combinations include capecitabine with docetaxel, 
paclitaxel, cisplatin, or oxaliplatin, and irinotecan. These 
therapies have yielded efﬁ  cacy data that compare favor-
ably with data from phase III trials of parenteral 5-FU in 
the ﬁ  rst-line metastatic setting, and they mostly are well 
tolerated.
A phase III study evaluated XP (capecitabine/cisplatin) 
vs FP (5-FU/cisplatin) in ﬁ  rst-line in patients with previously 
untreated measurable advanced gastric cancer.48 The patients 
received either oral capecitabine (1000 mg/m2 bid days 
1–14) + cisplatin (80 mg/m2 iv day 1) q3w (XP arm) or 
5-FU (800 mg/m2/day continuous infusion, days 1–5) + 
cisplatin (80 mg/m2 iv day 1) q3w (FP arm). XP requires 
1 day per 3 weeks in hospital; FP requires 5 days. Patients 
were treated until disease progression or unacceptable 
toxicity. Primary endpoint was non-inferiority (NI) in 
progression-free survival (PFS), deﬁ  ned as upper limit of 
95% conﬁ  dence interval (CI) of hazard ratio (HR)  1.4 
(ﬁ  rst test) and  1.25 (second test). Preliminary results 
presented at the annual meeting of ASCO 2006 showed that 
316 patients were enrolled in 13 countries (Table 1). Both 
arms were well balanced. The primary endpoint was met: 
capecitabine plus cisplatin was noninferior to ﬂ  uorouracil 
plus cisplatin in terms of progression-free survival (HR 0.81 
[95% CI 0.63, 1.04]). The most common treatment-related 
grade 3/4 AEs (XP vs FP) were: neutropenia (16% vs 19%), 
vomiting (7% vs 9%), stomatitis (2% vs 7%), diarrhea (5% vs OncoTargets and Therapy 2009:2 36
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5%), and anemia (5% vs 3%). The rate of all-grade HFS was 
low (22% vs 4%). These ﬁ  ndings suggest that capecitabine 
should become the ﬂ  uoropyrimidine of choice for advanced 
gastric cancer, given the efﬁ  cacy, reduced hospitalization 
time and simpliﬁ  ed regimen.
In another phase III trial (REAL-2) 1002 patients were 
randomly assigned to receive triplet therapy with epirubicin 
and cisplatin plus either ﬂ  uorouracil (ECF) or capecitabine 
(ECX) or triplet therapy with epirubicin and oxaliplatin 
plus either ﬂ  uorouracil (EOF) or capecitabine (EOX).49 
The primary end point was noninferiority in OS for the 
triplet therapies containing capecitabine as compared with 
ﬂ  uorouracil and for those containing oxaliplatin as compared 
with cisplatin. For the capecitabine-ﬂ  uorouracil comparison, 
the hazard ratio for death in the capecitabine group was 
0.86 (95% CI, 0.80–0.99); for the oxaliplatin-cisplatin com-
parison, the HR for the oxaliplatin group was 0.92 (95% CI, 
0.80–1.10). Median survival times in the ECF, ECX, EOF 
and EOX groups were 9.9 months, 9.9 months, 9.3 months 
and 11.2 months, respectively; survival rates at 1 year were 
37.7%, 40.8%, 40.4% and 46.8%, respectively. In the sec-
ondary analysis, OS was longer with EOX than with ECF, 
with a hazard ratio for death of 0.80 in the EOX group (95% 
CI, 0.66 to 0.97; p = 0.02). PFS and response rates did not 
differ signiﬁ  cantly among the regimens. Toxic effects of 
capecitabine and ﬂ  uorouracil were similar. Current studies 
are evaluating the efﬁ  cacy of capecitabine in combination 
with other agents, including oxaliplatin as well as in combi-
nation with radiation therapy.50
Pancreatic cancer
Initial phase II trials suggested that capecitabine had useful 
activity in pancreas cancer. A phase II trial by Cartwright 
et al investigated the safety and efﬁ  cacy of capecitabine in 
42 patients with advanced or metastatic pancreatic cancer. 
These patients received capecitabine monotherapy (1250 
mg/m2 twice daily on days 1–14 of a 21-day cycle).51 The 
safety proﬁ  le of capecitabine was similar to that observed 
with capecitabine in colorectal and breast cancer. The major 
grade 3/4 adverse events were diarrhea, HFS and nausea. 
There were three conﬁ  rmed partial responses (7%) and a 
further 17 patients (41%) achieved stable disease as their 
best response (including disease stabilization for 12 weeks 
in 11 patients [26%]). The median duration of response was 
2.8 months and the median OS was 6.0 months. In addi-
tion 10 patients (24%) achieved a positive Clinical Beneﬁ  t 
Response score and pain intensity was reduced in a further 
12 patients (29%).
As a result of pre-clinical evidence to suggest that 
capecitabine was synergistic with gemcitabine52 the combi-
nation went on to be tested in clinical trials. A multinational 
randomized trial by Herrmann et al reported no advantage 
of adding capecitabine, however subgroup analysis showed 
the beneﬁ  t for GemCap in patients with good performance 
status (HR 0.76; p   0.03).53 Another phase III random-
ized trial by Cunningham et al that compared single-agent 
gemcitabine with gemcitabine weekly for 3 weeks plus 
capecitabine 1660 mg/m2 daily for 21 days every 28-day 
cycle.54 Addition of capecitabine doubled response rate 
(14% vs 7%; p = 0.008) and improved OS (HR 0.80; 
p = 0.026). Myelosuppression was higher in incidence with 
the combination arm and HFS was only noted in combination 
arm. There have been three negative phase III trials of gem-
citabine plus a ﬂ  uoropyrimidine: “Why is this one positive?” 
The ﬁ  nal results of the study are anxiously awaited to answer 
this question.
Recently, ﬁ  nal results of the phase II study of gemcitabine, 
capecitabine, and bevacizumab in patients with advanced 
pancreatic cancer have been presented.55 Patients received 
bevacizumab 15 mg/kg iv day 1, capecitabine 650 mg/m2 
bid days 1–14, and gemcitabine 1000 mg/m2 iv days 1 
and 8; cycles repeated every 21 days. Among 50 patients, 
1 patient achieved complete response (CR) (2%), 10 partial 
response (20%) and 30 stable disease (60%). Median PFS 
and OS were 5.8 and 9.8 months, respectively. Grade 3/4 
toxicities included neutropenia 38%, thrombocytopenia 16%, 
Table 1 Efﬁ  cacy results of XP vs FP in gastric cancer48
XP (n = 160) FP (n = 156) p
Objective response rate (%) 41 29 0.03
Median progression-free survival (months)
Median overall survival (months)
5.6
10.5
5.0
9.3
0.0001*
0.003**
0.10***
0.27
*p-value for test of HR vs NI limit of 1.4; **similarly with NI limit of 1.25; ***superiority.
Abbreviations: XP, capecitabine/cisplatin; FP, 5-FU/cisplatin.OncoTargets and Therapy 2009:2 37
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thromboembolic events 14%, nausea 14%, hypertension 8%, 
and gastrointestinal bleeding 8%. One treatment-related death 
occurred (hemorrhage).
A phase I study of a chemotherapy doublet (gemcitabine 
plus capecitabine), combined with a biologic doublet 
(bevacizumab plus erlotinib) in patients with advanced pan-
creatic adenocarcinoma was presented at the annual meeting 
of ASCO, 2008 (the TARGET trial).56 Patients with advanced 
(including locally advanced) carcinoma were treated at 
4 cohorts of escalating capecitabine doses (days 1–21): 
910 mg/m2, 1160 mg/m2, 1400 mg/m2 and 1660 mg/m2. 
The doses of co-administered gemcitabine (1000 mg/m2 
days 1, 8 and 15), bevacizumab (5 mg/kg days 1 and 15), 
and erlotinib (100 mg/day) every 28 days were constant. 
Dose-limiting toxicity occurred in 1 patient at 910 mg/m2 
(grade 3 epistaxsis) and 2 patients at 1660 mg/m2 (grade 3 
diarrhea, and grade 3 skin rash for more than 7 days). No 
patient developed gastrointestinal perforation or pneumonitis, 
while a gastrointestinal bleed (grade 1) was seen in 1 patient. 
Among evaluable 14 patients, there were 5 conﬁ  rmed partial 
responses (36%) and a 50% decrease in CA 19-9 by 8 weeks 
was seen in 9 patients (64%). The maximal tolerable dose of 
capecitabine in this four-drug cytotoxic/biologic combination 
is 1660 mg/m2 and a follow-on phase II study is planned.
Kulke et al performed a phase II study of capecitabine 
plus erlotinib in gemcitabine-refractory advanced pancreatic 
cancer.57 Thirty patients with gemcitabine-refractory meta-
static pancreatic cancer were treated with capecitabine, 
administered at a dose of 1000 mg/m2 twice daily for 2 weeks, 
followed by a 1-week break. All patients also received 
erlotinib 150 mg daily. Treatment with capecitabine and 
erlotinib in gemcitabine-refractory patients was associated 
with an overall objective radiologic response rate of 10% 
and median survival duration of 6.5 months. In addition, 
17% of the treated patients experienced decreases in tumor 
marker (CA 19-9) levels of more than 50% from baseline. 
Common toxicities included diarrhea, skin rash, fatigue, and 
HFS. This regimen may offer an acceptable treatment option 
in patients who experience treatment failure with standard 
ﬁ  rst-line therapy with gemcitabine.
Oral capecitabine has been used in pancreatic cancer as 
a radio-sensitizing agent. A phase I study done by Saif et al 
showed that capecitabine 800 mg/m2 bid with concurrent 
external radiation therapy is feasible in patients with locally 
advanced pancreatic cancer.58 This study was further con-
ﬁ  rmed by a phase II study.59 This approach offers an easy 
alternative to intravenous ﬂ  uorouracil as a radiosensitizer 
but more studies are needed to be done.
Capecitabine in anal cancer
Since 5-ﬂ  uorouracil (5-FU) + mitomycin C (MMC)-based 
chemoradiotherapy is standard treatment for patients with 
epidermoid anal carcinoma, a recent phase II trial determined 
the feasibility, toxicity, and efﬁ  cacy of capecitabine, MMC 
and radiotherapy (RT) in anal cancer patients. Radio-
therapy comprised the schedule of the UK Anal Cancer 
Trial (ACT) II trial (50.4 Gy in 28 fractions of 1.8 Gy).60 
With MMC (12 mg/m2) on day 1 and capecitabine on each 
RT treatment day in 2 divided doses (825 mg/m2 bid). 
The endpoints were CR at 4 weeks, local control at 6 months 
and toxicity.
Thirty-one patients entered the trial. The median age 
was 61 years (range 45–86) with 14 males and 17 females. 
Compliance with chemotherapy with no dose interruptions 
or delays was 68%, and with RT was 81%. Eighteen (58%) 
patients completed both modalities of treatment as planned. 
Dose-limiting Grade 3 or 4 diarrhea was seen in 1 of 
31 patients. Three patients experienced Grade 3 neutropenia. 
There were no treatment-related deaths. Four weeks follow-
ing completion of chemoradiation, 24 patients (77%) had a 
complete clinical response and 4 (16%) a partial response. 
With a median follow-up of 14 months, 3 locoregional 
relapses occurred.
Capecitabine with MMC and RT in patients with anal 
carcinoma is well tolerated, with minimal toxicity and 
acceptable compliance. Further testing of this schedule in 
Phase III studies is undergoing.
Capecitabine in hepatobiliary cancers
Capecitabine is also actively in hepatobiliary tumors. Patt 
et al performed a retrospective analysis of all patients with 
hepatocellular carcinoma (HCC), cholangiocarcinoma 
(CCA), or gallbladder carcinoma (GBC) who were treated 
with oral capecitabine.61 A total of 63 patients were treated 
with capecitabine (37 with HCC, 18 with CCA, 8 with GBC). 
Capecitabine 1000 mg/m2 was administered twice daily for 
14 days. Treatment was repeated every 21 days. Each patient 
received 1 to 15 treatment cycles. Nine (14%) to 11% of 
patients with HCC, 6% of patients with CCA, and 50% of 
patients with GBC had either a CR or a partial response. A CR 
was radiologically conﬁ  rmed in 1 patient with HCC and in 
2 patients with GBC. The median survival times were 10.1 
months (95% CI 4.5–15.7 months) for patients with HCC, 
8.1 months (95% CI, 7.4–8.9 months) for patients with CCA, 
and 9.9 months (95% CI, 4.4–15.4 months) for patients with 
GBC. The most common toxicity was HFS (37%). Grade 3 
thrombocytopenia occurred in 8% of patients with HCC. OncoTargets and Therapy 2009:2 38
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No other signiﬁ  cant toxicities were observed. For all patients, 
response to treatment was positively correlated with survival 
and decline in tumor markers. The author concluded that 
capecitabine is safe for patients with hepatobiliary carcinoma, 
including those with cirrhosis. The antitumor activity of 
single-agent capecitabine was most pronounced in patients 
with GBC, was modest in patients with HCC, and was poor 
in patients with CCA.
The combination of capecitabine with platinum 
compounds as well as triplet has also been studied in small 
studies.62–64 Worth-mentioning studies may include but are 
not limited to the FFCD 03-03 trial: a multicenter phase II 
trial of capecitabine plus oxaliplatin (XELOX); capecitabine 
plus cisplatin; and triplet of doxorubicin, cisplatin and 
capecitabine for metastatic hepatocellular carcinoma.
Discussion
Capecitabine is currently the only novel, orally home-
administered fluorouracil prodrug. Capecitabine could 
replace 5-FU either as a single agent or as the combina-
tion partner for chemotherapy or radiotherapy in nearly all 
gastrointestinal malignancies. It offers patients more freedom 
from hospital visits and less inconvenience and complications 
associated with infusion devices. The drug has been exten-
sively studied in large clinical trials in many gastrointestinal 
and non-gastrointestinal malignancies, and compares favor-
ably with ﬂ  uorouracil with a safe toxicity proﬁ  le, consisting 
mainly of gastrointestinal and dermatologic adverse effects. 
Whereas gastrointestinal events and HFS occur often with 
capecitabine, the tolerability proﬁ  le is comparatively favor-
able. Prompt recognition of severe adverse effects is the key 
to successful management of capecitabine.
Ongoing and future clinical trials will continue to exam-
ine, and likely expand, the role of capecitabine as a single 
agent and/or in combination with other anticancer agents 
for the treatment of other solid tumors, both in the advanced 
palliative and adjuvant settings.
It is important to appreciate that the combination of 
capecitabine with agents such as irinotecan and oxaliplatin 
is more than just replacing the backbone of 5-FU. There 
is a molecular rationale: XELIRI → capecitabine inhibits 
Bcl-2, a protein that prevents tumor cell death (apoptosis) 
by radiation, taxanes, oxaliplatin and irinotecan, and 
XELOX → capecitabine inhibits ERCC-1, a DNA repair pro-
tein that blocks the cytotoxic activity of radiation and oxali-
platin. In addition, irinotecan and oxaliplatin induce TP in 
tumors. Similarly, our group has also investigated the effect 
of radiation on TP and showed that radiation upregulates TP 
in tumors, but not in normal cells. This combined modality 
then synergizes in both directions: radiation as chemosensi-
tizer by upregulating TP and capecitabine after conversion 
to 5-FU radiosensitizing the tumor to radiation effects. This 
combination is of utmost interest in clinical investigation in 
many tumors, especially rectal cancer.
It is also important to appreciate that dose reductions 
in pivotal studies in colorectal cancer indicated that dose 
reduction did not reduce the efﬁ  cacy of capecitabine.65 
Currently, 2500 mg/m2 is the FDA-approved dose of 
capecitabine but this dose is not tolerated by patients in the 
US. Another issue related to the dose is the two different 
strengths of capecitabine (150 and 500 mg). Some physicians 
prefer to prescribe the dose with 500 mg capsules only to pre-
vent any overdose or underdose by a patient. We also suggest 
that the dose should be rounded to the closest ﬁ  gure to make a 
dose that contains a similar strength of capecitabine capsules 
for convenience and to decrease the risk as noted above.
One interesting observation was recently published by 
Hennig et al66 who compared overall acceptability to patients 
between intravenous FU/LV or oral capecitabine. Patients 
scheduled for adjuvant single-agent ﬂ  uoropyrimidine therapy 
were randomly assigned to receive once-weekly FU/LV 
(425 mg/m2 FU, 45 mg LV) for 6 weeks, followed by two 
3-week cycles of capecitabine (1250 mg/m2 twice daily, 
days 1 through 14), or the same treatments but in reverse 
order. After 12 weeks, the patients were asked which treat-
ment they preferred, and received the preferred treatment for 
an additional 12 weeks. The primary end point was patient 
preference. After 40 of the planned 74 patients had been 
randomly assigned, real-time adverse event monitoring led 
to early trial closure because of excess sequence-speciﬁ  c 
toxicity. In chemotherapy-naïve patients, capecitabine 
produced more toxicity than FU/LV, but at levels in line 
with previously reported data. However, treatment with 
capecitabine after FU/LV caused markedly increased tox-
icity, indicating a sequence-speciﬁ  c interaction as shown 
in Table 2. The mechanism has not been determined, but 
interaction with intracellularly retained folate after FU/LV 
therapy is a possibility. Oncologists need to be aware of this 
risk if considering crossing patients over from FU/LV to 
capecitabine-based regimens.
Education of the patient and the caretaker is paramount 
in management of capecitabine toxicity. There are several 
drug interactions with capecitabine and the patient must 
be educated to prevent adverse outcomes. Data on patients 
with DPD deﬁ  ciency and tolerance of capecitabine are 
scarce.67 We suggest that it is still important to suspect and OncoTargets and Therapy 2009:2 39
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test for DPD deﬁ  ciency in patients on capecitabine with any 
manifestation of toxicity.
Summary
In summary, most current data indicate that capecitabine is not 
inferior to infusional 5-FU and offers added beneﬁ  t of conve-
nience. Future studies should also aim at evaluating the drug 
cost. For those parts of the world in which hospitalization 
is required to deliver ﬂ  uorouracil by infusion, an outpatient 
oral regimen has an advantage. Capecitabine offers not only 
efﬁ  cacy in different gastrointestinal and non-gastrointestinal 
malignancies, but also broadens the availability and 
convenience of treatment.
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